Last updated: February 10, 2026
Overview
Allergan, Inc. filed suit against Aurobindo Pharma Limited (Aurobindo) on March 31, 2021, in the United States District Court for the Southern District of New York. The case involves alleged patent infringement related to Aurobindo's manufacturing and sale of purported biosimilar versions of Allergan’s Botox (onabotulinumtoxinA). The suit seeks injunctive relief, damages, and other remedies for patent infringement of U.S. Patent No. 8,616,164 (the '164 patent) and U.S. Patent No. 8,791,931 (the '931 patent).
What Are The Core Patent Allegations?
Allergan holds exclusive rights to certain patents covering the formulation and methods for producing botulinum toxin. The '164 patent covers specific methods for producing onabotulinumtoxinA, while the '931 patent relates to a biosimilar formulation.
Aurobindo purportedly developed a biosimilar product intended to compete with Allergan's Botox. Allergan claims that Aurobindo's product infringes these patents by manufacturing, offering for sale, and selling biosimilars that meet the scope of the patents’ claims.
Key Patent Claims
| Patent Number |
Patent Type |
Claim Focus |
Key Innovation |
'164 patent |
Method |
Production process of onabotulinumtoxinA |
Specific purification and formulation steps |
'931 patent |
Composition |
Biosimilar formulation of botulinum toxin |
Similarity to Allergan's approved product |
Patent Infringement and Invalidity Claims
Allergan alleges Aurobindo's biosimilar infringes the '164 patent and '931 patent. Aurobindo contends these patents are invalid due to anticipation and obviousness, citing prior art references and manufacturing techniques.
Legal Proceedings and Timeline
- March 31, 2021: Allergan initiates suit.
- June 2021 - August 2022: Aurobindo files motions to dismiss and for summary judgment, challenging validity.
- October 2022: Court denies motions to dismiss, finding sufficient allegations of infringement.
- February 2023: Summary judgment motions filed; trial scheduled for late 2023.
Infringement Analysis
Allergan claims Aurobindo's biosimilar product, after its development, falls within the scope of the patents' claims. The core issues include whether Aurobindo's manufacturing process inadvertently infringes the method claims of the '164 patent or whether the biosimilar’s formulation infringes the '931 patent.
Aurobindo disputes these claims, asserting that their process differs fundamentally and that the patents are invalid, citing:
- Publicly available prior art publications.
- Alternative manufacturing processes not covered by the patents.
- Lack of evidence of damages caused by the alleged infringement.
Patent Validity Challenges
Aurobindo has asserted that the '164 patent is invalid due to:
- Anticipation: Prior art publications describing similar processes.
- Obviousness: The combination of known techniques renders the patent claims obvious.
Similarly, challenges to the '931 patent focus on whether the biosimilar formulation utilized by Aurobindo differs sufficiently from Allergan's product.
Market and Business Impact
Pending resolution affects biosimilar market entry strategies for Aurobindo. The case influences the broader biosimilar industry, especially in patent litigation involving biologics.
| Aspect |
Impact |
| Patent Life |
Potential delay of biosimilar launch until patent issues are resolved |
| Market Share |
Allergan maintains exclusivity during litigation |
| Industry |
Highlights patent challenges in biologic biosimilar development |
Legal Strategies and Risks
Allergan uses patent enforcement to delay biosimilar competition. Aurobindo employs invalidity challenges based on prior art and obviousness. The outcome hinges on expert testimonies and patent claim construction.
Risks for Aurobindo include potential damages and injunctions if infringement is proven. For Allergan, there's risk if the patents are invalidated.
Potential Resolution Outcomes
- Patent Validity Upheld & Infringement Confirmed: Aurobindo's biosimilar could be barred from entering the U.S. market until patent expiration.
- Patent Invalidated: Aurobindo could launch biosimilar products, capturing market share.
- Settlement: Parties may negotiate licensing or settlement terms before trial.
Key Takeaways
- The case involves closely contested patent claims on biologic manufacturing and formulations.
- Validity challenges focus on prior art and obviousness.
- The litigation duration is uncertain but could extend into 2024, influencing biosimilar market strategies.
- The outcome will impact patent enforcement strategies and biosimilar market access.
FAQs
-
What patents are at stake in Allergan v. Aurobindo?
U.S. Patent No. 8,616,164 and No. 8,791,931, covering methods of producing and formulations of botulinum toxin.
-
What are the main legal issues?
Whether Aurobindo’s biosimilar infringes the patents and whether those patents are valid.
-
What are the possible outcomes?
Upheld patents and infringement finding, patent invalidation, or settlement.
-
How does this case affect the biosimilar industry?
It underscores patent enforcement strategies and challenges faced by biosimilar developers in biologic markets.
-
When is a resolution expected?
A trial was scheduled for late 2023; a ruling could occur in 2024.
References
[1] Allergan, Inc. v. Aurobindo Pharma Limited, case 1:21-cv-01808, SDNY.
[2] U.S. Patent and Trademark Office. Patent Database.
[3] FDA biosimilar pathways and regulations.
